| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Lung and Thoracic cancer
Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non–Small Cell Lung Cancer
Beung-Chul Ahn, Charny Park, Moon Soo Kim, Jong Mog Lee, Jin Ho Choi, Hyae Young Kim, Geon Kook Lee, Namhee Yu, Youngjoo Lee, Ji-Youn Han
Cancer Res Treat. 2024;56(1):70-80.   Published online June 21, 2023    DOI: https://doi.org/10.4143/crt.2023.482
                        Supplementary      
miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
Mi Seong Kim, So Hui Kim, Sei Hoon Yang, Min Seuk Kim
Cancer Res Treat. 2022;54(2):445-457.   Published online August 3, 2021    DOI: https://doi.org/10.4143/crt.2021.622
                           Web of Science 5  Crossref 3
Endocrine cancer
Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea
Hwa Young Ahn, Ra-Yeong Song, Hye Shin Ahn, Hee Sung Kim
Cancer Res Treat. 2021;53(4):1204-1212.   Published online February 10, 2021    DOI: https://doi.org/10.4143/crt.2020.1201
                           Web of Science 5  Crossref 4
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Res Treat. 2020;52(2):543-551.   Published online November 8, 2019    DOI: https://doi.org/10.4143/crt.2019.305
                        Supplementary         Web of Science 15  Crossref 14
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat. 2020;52(1):284-291.   Published online July 23, 2019    DOI: https://doi.org/10.4143/crt.2019.200
                           Web of Science 5  Crossref 4
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Chang-Min Choi, Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Boram Lee, Young-Joo Won, Young-Chul Kim
Cancer Res Treat. 2019;51(4):1400-1410.   Published online February 25, 2019    DOI: https://doi.org/10.4143/crt.2018.704
                        Supplementary         Web of Science 50  Crossref 48
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):718-726.   Published online September 3, 2018    DOI: https://doi.org/10.4143/crt.2018.324
                           Web of Science 11  Crossref 11
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018    DOI: https://doi.org/10.4143/crt.2018.151
                        Supplementary         Web of Science 43  Crossref 36
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Cancer Res Treat. 2019;51(2):502-509.   Published online June 13, 2018    DOI: https://doi.org/10.4143/crt.2018.117
                        Supplementary         Web of Science 72  Crossref 63
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Res Treat. 2019;51(1):169-177.   Published online April 5, 2018    DOI: https://doi.org/10.4143/crt.2017.491
                           Web of Science 5  Crossref 5
Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee
Cancer Res Treat. 2019;51(1):158-168.   Published online April 2, 2018    DOI: https://doi.org/10.4143/crt.2018.084
                        Supplementary         Web of Science 16  Crossref 14
Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee
Cancer Res Treat. 2018;50(4):1351-1361.   Published online January 17, 2018    DOI: https://doi.org/10.4143/crt.2017.487
                        Supplementary         Web of Science 12  Crossref 11
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang
Cancer Res Treat. 2018;50(4):1294-1303.   Published online January 4, 2018    DOI: https://doi.org/10.4143/crt.2017.512
                        Supplementary         Web of Science 47  Crossref 43
Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang
Cancer Res Treat. 2018;50(4):1164-1174.   Published online December 11, 2017    DOI: https://doi.org/10.4143/crt.2017.460
                        Supplementary         Web of Science 6  Crossref 4
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
Cancer Res Treat. 2018;50(3):908-916.   Published online September 19, 2017    DOI: https://doi.org/10.4143/crt.2017.378
                           Web of Science 33  Crossref 26
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Jong Ho Cho, Wei Zhou, Yoon-La Choi, Jong-Mu Sun, Hyejoo Choi, Tae-Eun Kim, Marisa Dolled-Filhart, Kenneth Emancipator, Mary Anne Rutkowski, Jhingook Kim
Cancer Res Treat. 2018;50(1):95-102.   Published online March 17, 2017    DOI: https://doi.org/10.4143/crt.2016.591
                           Web of Science 22  Crossref 19
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
Cancer Res Treat. 2017;49(4):937-946.   Published online January 6, 2017    DOI: https://doi.org/10.4143/crt.2016.423
                           Web of Science 8  Crossref 5
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee
Cancer Res Treat. 2017;49(1):10-19.   Published online May 3, 2016    DOI: https://doi.org/10.4143/crt.2016.058
                        Supplementary         Web of Science 37  Crossref 35
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Vivek Narayan, Ronac Mamtani, Stephen Keefe, Thomas Guzzo, S. Bruce Malkowicz, David J. Vaughn
Cancer Res Treat. 2016;48(3):1084-1091.   Published online December 2, 2015    DOI: https://doi.org/10.4143/crt.2015.405
                           Web of Science 13  Crossref 12
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park
Cancer Res Treat. 2016;48(2):458-464.   Published online October 14, 2015    DOI: https://doi.org/10.4143/crt.2015.135
                           Web of Science 1  Crossref 1
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park, Sung Hwan Jeong, Jinny Park, Jae Hoon Lee, Dong Bok Shin
Cancer Res Treat. 2016;48(1):80-87.   Published online March 2, 2015    DOI: https://doi.org/10.4143/crt.2014.307
                           Web of Science 15  Crossref 8
Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
Chi Hong Kim, Seung Hoon Kim, Sonya Youngju Park, Jinyoung Yoo, Sung Kyoung Kim, Hoon Kyo Kim
Cancer Res Treat. 2015;47(4):653-660.   Published online January 30, 2015    DOI: https://doi.org/10.4143/crt.2014.118
                           Web of Science 23  Crossref 18
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
Cancer Res Treat. 2015;47(4):630-637.   Published online February 16, 2015    DOI: https://doi.org/10.4143/crt.2014.244
                           Web of Science 22  Crossref 12
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
Cancer Res Treat. 2015;47(4):549-554.   Published online April 29, 2015    DOI: https://doi.org/10.4143/crt.2014.362
                           Web of Science 6  Crossref 7
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
June-Koo Lee, Dong-Wan Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Young-Joo Kim, Dae Seog Heo
Cancer Res Treat. 2015;47(2):182-188.   Published online September 12, 2014    DOI: https://doi.org/10.4143/crt.2013.227
                           Web of Science 4  Crossref 2
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat. 2014;46(4):323-330.   Published online July 14, 2014    DOI: https://doi.org/10.4143/crt.2013.120
                           Web of Science 23  Crossref 19
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
Cancer Res Treat. 2013;45(2):95-102.   Published online June 30, 2013    DOI: https://doi.org/10.4143/crt.2013.45.2.95
                           Crossref 16
Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?
Jun Ah Lee, Yunmi Ko, Dong Ho Kim, Jung Sub Lim, Chang-Bae Kong, Wan Hyeong Cho, Dae-Geun Jeon, Soo-Yong Lee, Jae-Soo Koh
Cancer Res Treat. 2012;44(3):202-209.   Published online September 30, 2012    DOI: https://doi.org/10.4143/crt.2012.44.3.202
                           Crossref 26
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy
Cancer Res Treat. 2012;44(2):74-84.   Published online June 30, 2012    DOI: https://doi.org/10.4143/crt.2012.44.2.74
                           Crossref 5
Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization
Kwang Hyun Baek, Min Eui Hong, Yoon Yang Jung, Chung Hun Lee, Tae Jin Lee, Eon Sub Park, Mi Kyung Kim, Jae Hyung Yoo, Soo Whan Lee
Cancer Res Treat. 2012;44(1):50-56.   Published online March 31, 2012    DOI: https://doi.org/10.4143/crt.2012.44.1.50
                           Crossref 33
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.1
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI